ONC.TO - Oncolytics Biotech Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.6400
-0.0100 (-1.54%)
At close: 1:54PM EDT
Stock chart is not supported by your current browser
Previous Close0.6500
Open0.6300
Bid0.6300 x 0
Ask0.6500 x 0
Day's Range0.6300 - 0.6500
52 Week Range0.4800 - 4.5500
Volume59,041
Avg. Volume68,279
Market Cap16.006M
Beta (3Y Monthly)2.52
PE Ratio (TTM)N/A
EPS (TTM)-1.0150
Earnings DateMar 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.33
  • ACCESSWIRE

    Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 17, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, is pleased to announce the appointment of Leonard Kruimer, MBA, CPA, to Oncolytics' Board of Directors. Mr. Kruimer has more than 30 years of experience in corporate finance, planning and strategy, including 20 years in senior management positions in private and publicly listed biotechnology and life science companies. Notably, Mr. Kruimer served as CFO and Executive Committee Member of the Netherlands-based vaccine company Crucell from 1998 through 2011, and an integral part of the corporate sale to Johnson & Johnson for US$2.3 billion.

  • ACCESSWIRE

    Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 15, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the results of a metanalysis of 13 clinical studies of the Company's systemically delivered oncolytic reovirus, pelareorep, were presented during a podium presentation at the annual International Oncolytic Virus Conference (IOVC), hosted at the Mayo Clinic in Rochester, MN on October 9-12, 2019. The analyses examined the effectiveness of viral replication within the tumors of patients treated systemically with pelareorep. The data demonstrated that, unlike other oncolytic viruses that require intra-tumoral delivery, intravenous (IV) systemic delivery of pelareorep resulted in 81% of patient tumor samples across multiple types of cancer testing positive for virus replication, with no infection in normal tissue.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 1, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today ...

  • ACCESSWIRE

    Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 30, 2019 / Oncolytics Biotech® Inc. (ONCY)(ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that its President and Chief Executive Officer, Matt Coffey, Ph.D., MBA, was presented with the Scientific Achievement and Innovation Award by BioAlberta, the province's life sciences industry association. "I am honored to receive this recognition from BioAlberta for my work in oncolytic viruses, which started a little more than twenty years ago at the University of Calgary," said Dr. Coffey. Most importantly, we've learned about the ability of oncolytic viruses to wake up the immune system.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Upcoming Presentation at the 12th Annual International Oncolytics Virus Conference

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 25, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will have an oral presentation at the 12th Annual International Oncolytic Virus Conference. The conference takes place at the Mayo Civic Center in Rochester, Minnesota, from October 9 - 12. The presentation, "Systemic administration of oncolytic reovirus, pelareorep, a metanalysis on the efficiency of tumor delivery", by Grey Wilkinson, PhD, Scientist of Translational Medicine at Oncolytics Biotech, will examine the efficiency of viral delivery and replication in tumor tissue across several clinical studies.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Upcoming Conference Participation

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 23, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today ...

  • ACCESSWIRE

    Oncolytics Biotech(R) Receives Nasdaq Notification Letter

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 20, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq"). The letter notifies the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, since the closing bid price for the Company's common shares listed on Nasdaq was below USD $1.00 for 30 consecutive trading days.

  • ACCESSWIRE

    Oncolytics Biotech(R) to Present at the Ladenburg Thalmann Healthcare Conference

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 17, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Matt Coffey, President & CEO of Oncolytics Biotech, will present at the Ladenburg Thalmann Healthcare Conference at 11:00 am Eastern Time on Tuesday, September 24, 2019. A live audio link to the webcast session will be available on the Company's website at http://www.oncolyticsbiotech.com/investor-centre/presentations. Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.

  • ACCESSWIRE

    Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 5, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Kirk Look, Chief Financial Officer of Oncolytics Biotech, will present at the H.C. Wainwright 21st Annual Global Investment Conference at 5:30 pm Eastern Time on Monday, September 9, 2019. A live audio link to the webcast session will be available on the Company's website at http://www.oncolyticsbiotech.com/investor-centre/presentations. Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.

  • ACCESSWIRE

    Oncolytics Biotech(R) to Host Corporate Update Call to Discuss Recent Highlights and Expanded Catalysts and Milestones

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 4, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced it will host a conference call and live webcast for Analysts and Institutional Investors at 8:30 a.m. ET on Thursday, September 5, 2019. The call will focus on a clinical and business development update, the current financial position and the recently updated list of catalysts and milestones. Overseas callers should contact investor relations for the toll-free dial information for their country.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Closing of Its Public Offering of Common Shares and Warrants

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / August 16, 2019 / Oncolytics Biotech® Inc. (ONCY)(ONC.TO) (the “Company”), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the closing of its previously announced underwritten public offering (the “Offering”). Oncolytics sold 4,619,773 common shares and warrants to purchase up to 4,619,773 common shares, at a purchase price of USD $0.81 (approximately CDN $1.07) per share and warrant, for gross proceeds of approximately USD $3.7 million (approximately CDN $4.9 million). Oncolytics expects to use the net proceeds from the Offering for research and development activities and working capital purposes.

  • ACCESSWIRE

    CORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and Warrants

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / August 14, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO) (the “Company”), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, provides an update to confirm that its previously announced underwritten public offering of USD $3.7M (CDN $4.9M) was priced at USD $0.81 (CDN $1.07). Oncolytics Biotech® Inc. (ONCY) (ONC.TO) (the “Company”), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 4,619,773 common shares and warrants to purchase up to 4,619,773 common shares at a combined public offering price of $0.81 per share and warrant, resulting in gross proceeds of approximately USD 3.7M.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Pricing of Its Public Offering of Common Share and Warrants

    SAN DIEGO, CA & CALGARY, AB / ACCESSWIRE / August 14, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO) (the “Company”), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 4,619,773 common shares and warrants to purchase up to 4,619,773 common shares at a combined public offering price of $0.81 per share and warrant, resulting in gross proceeds of approximately USD 3.7M. Each warrant has an exercise price of $0.90 per common share, is exercisable immediately and will expire 5 years from the date of issuance. The common shares and the accompanying warrants can only be purchased together in this Offering but will be issued separately.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Preliminary AWARE-1 Trial Data Demonstrating Viral Replication and Promotion of Inflammation Following Systemic Administration of Pelareorep When Combined with Tecentriq(R)

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / July 23, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced completion of the three patient run-in for the AWARE-1 study in early-stage breast cancer combining pelareorep and Tecentriq® (atezolizumab). All three patients demonstrated immunohistochemically positive viral replication in the tumor mass - two of the three patients showed greater than 50% of the tumor cells infected - following intravenous administration, generating inflammation and T cell recruitment at the tumor site. Increases in PD-L1 expression on tumor cells were noted in all patients, and early data suggest a correlation between T cell clonality and viral replication with highly infected tumors.

  • ACCESSWIRE

    Oncolytics Biotech (R) to Host Conference Call to Discuss Co-Development Agreement with Pfizer and Merck KGaA

    SAN DIEGO, CA, and CALGARY, AB / ACCESSWIRE / June 5, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced that the company will host a conference call to discuss the co-development agreement with Pfizer and Merck KGaA. Oncolytics management will host a conference call with a question and answer session for Analysts and Institutional Investors today, Wednesday, June 5, 2019 at 8:30 am ET. A live audio webcast of the call will be accessible on the Investor Relations page of Oncolytics' website at www.oncolyticsbiotech.com and will be archived for three months.

  • ACCESSWIRE

    Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer

    Phase 2 BRACELET-1 study to evaluate Oncolytics' systemically delivered oncolytic virus, pelareorep, in combination with paclitaxel and anti-PD-L1 antibody avelumab SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE ...

  • ACCESSWIRE

    Oncolytics Biotech(R) to Present at the 9th Annual LD Micro Invitational Investor Conference

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 29, 2019 / Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today ...

  • Imagine Owning Oncolytics Biotech (TSE:ONC) And Trying To Stomach The 81% Share Price Drop
    Simply Wall St.

    Imagine Owning Oncolytics Biotech (TSE:ONC) And Trying To Stomach The 81% Share Price Drop

    This week we saw the Oncolytics Biotech Inc. (TSE:ONC) share price climb by 10%. But will that repair the damage for...

  • ACCESSWIRE

    Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 16, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an abstract highlighting additional immune-based biomarker data used to help predict patient response to pelareorep in combination with checkpoint inhibitor therapy. The abstract was published online as part of the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in the Meeting Proceedings, an online supplement of ASCO's Journal of Clinical Oncology. The abstract, titled, "Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC)," describes further immune analysis of the peripheral blood of patients from REO 024, a completed phase 1b study of pelareorep and Keytruda® (pembrolizumab) in combination with chemotherapy in patients with advanced (second-line) pancreatic cancer.

  • ACCESSWIRE

    Oncolytics Biotech (R) Reports 2019 First Quarter Financial Results and Operational Highlights

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 3, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter ended March 31, 2019. ''Our primary focus remains the breast cancer program and the timely completion of our AWARE-1 study of pelareorep in combination with the immune checkpoint inhibitor Tecentriq.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Voting Results from the Annual General Meeting of Shareholders

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 3, 2019 / Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today ...

  • ACCESSWIRE

    Oncolytics Biotech(R) to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 23, 2019 / Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today ...

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces First Patient Treated in Company's AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 8, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient has been treated in the AWARE-1 window of opportunity (WOO) study that is being conducted in collaboration with SOLTI, an academic research group dedicated to clinical and translational research in breast cancer. Patients will receive the appropriate intervention for their breast cancer sub-type, plus pelareorep, with or without Tecentriq® (atezolizumab), followed by surgery. "We are pleased to have treated the first patient in our window of opportunity study that will yield important results confirming both our recently identified biomarker and pelareorep's ability to prime an antitumor immune response," said Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech.

  • ACCESSWIRE

    Oncolytics Biotech(R) to Host Key Opinion Leader Meeting on the Emerging Role of Biomarkers and Oncolytic Viruses in the Treatment of Cancer

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 4, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a Key Opinion Leader meeting to discuss the emerging role of biomarkers and oncolytic viruses in the treatment of cancer on Thursday, April 11, 2019 at 12 pm EDT in New York City. The event will feature presentations by company management and Key Opinion Leader Dirk Arnold MD, PhD, Executive Board Member of the European Society of Medical Oncology (ESMO) & Chief of Oncology at Asklepios Klinik Altona, who will discuss biomarkers, their importance in trials, their influence on large pharma and their impact in both clinical and commercial settings, as well as recent biomarker data from Oncolytics.

  • ACCESSWIRE

    Oncolytics Biotech(R) to Present at the 18th Annual Needham Healthcare Conference

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 3, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today ...